Evolus (EOLS) Stock Forecast & Price Target

Compare

562 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

EOLS Analyst Ratings

Strong Buy

5 Buy

1 Hold

0 Sell

Based on 6 analysts giving stock ratings to

Evolus

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

EOLS Stock 12 Month Forecast

Average Price Target

$19.25

▲(173.44% Upside)

Based on 6 Wall Street analysts offering 12 month price targets for Evolus in the last 3 months. The average price target is $19.25 with a high forecast of $20.00 and a low forecast of $18.00. The average price target represents a 173.44% change from the last price of $7.04.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","9":"$9","13":"$13","17":"$17","21":"$21"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$19.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$18.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,9,13,17,21],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.82,7.833846153846154,8.847692307692308,9.861538461538462,10.875384615384615,11.88923076923077,12.903076923076924,13.916923076923077,14.930769230769231,15.944615384615386,16.95846153846154,17.972307692307695,18.986153846153847,{"y":20,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.82,7.776153846153846,8.732307692307693,9.688461538461539,10.644615384615385,11.600769230769231,12.556923076923077,13.513076923076923,14.46923076923077,15.425384615384615,16.38153846153846,17.337692307692308,18.293846153846154,{"y":19.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.82,7.680000000000001,8.540000000000001,9.4,10.26,11.120000000000001,11.98,12.84,13.7,14.56,15.42,16.28,17.14,{"y":18,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":13.51,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.04,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.97,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.59,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.99,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.8,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.97,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.2,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.15,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.5,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.15,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.46,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.82,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$20.00

Average Price Target$19.25

Lowest Price Target$18.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Uy Ear

Mizuho Securities

$19

Buy

169.89%

Upside

Reiterated

12/11/25

Mizuho Securities Keeps Their Buy Rating on Evolus (EOLS)We maintain our $19 PT and Outperform rating given attractive valuation (~1.5x EV/2026 sales) --which was a key theme among investors -- and compelling long-term prospects of Evolus' business following the recovery of the injectable facial aesthetics markets.

Douglas Tsao

H.C. Wainwright

$20

Buy

184.09%

Upside

Reiterated

12/02/25

Evolus's Strategic Growth and Market Resilience Drive Buy RatingValuation and Risks. Our Buy rating and price target of $20 for Evolus are based on 5x our 2035 discounted risk-adjusted revenue estimate of $312M. We adjust each pipeline asset for the probability of success (PoS). We assign the 100% as it is a commercialized product; we assign the at 60%. Key risks include disruption to supply chain, inability to capture market share due to competitive response from larger competitors, the effects from COVID-19, and possible dilution.

Annabel Samimy

Stifel Nicolaus

$20

Buy

184.09%

Upside

Reiterated

11/06/25

Stifel Nicolaus Keeps Their Buy Rating on Evolus (EOLS)

Serge Belanger

Needham

―

Hold

―

Assigned

11/06/25

Evolus Maintained at Hold Amid Mixed Financial Performance and Market ChallengesWe maintain our Hold rating given continuing macro pressures and negative consumer sentiment weighing down on the aesthetics market, and restricting growth of toxins and fillers.

Sam Eiber

BTIG

$18

Buy

155.68%

Upside

Reiterated

11/06/25

Analysts Offer Insights on Healthcare Companies: Accuray (NASDAQ: ARAY), Evolus (NASDAQ: EOLS) and Caris Life Sciences, Inc. (NASDAQ: CAI)

Marc Goodman

Leerink Partners

―

Buy

―

Reiterated

10/07/25

Leerink Partners Keeps Their Buy Rating on Evolus (EOLS)

Balaji Prasad

Barclays

$22→$25

Buy

255.11%

Upside

Reiterated

03/05/25

Barclays Reaffirms Their Buy Rating on Evolus (EOLS)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Uy Ear

Mizuho Securities

$19

Buy

169.89%

Upside

Reiterated

12/11/25

Douglas Tsao

H.C. Wainwright

$20

Buy

184.09%

Upside

Reiterated

12/02/25

Annabel Samimy

Stifel Nicolaus

$20

Buy

184.09%

Upside

Reiterated

11/06/25

Stifel Nicolaus Keeps Their Buy Rating on Evolus (EOLS)

Serge Belanger

Needham

―

Hold

―

Assigned

11/06/25

Sam Eiber

BTIG

$18

Buy

155.68%

Upside

Reiterated

11/06/25

Analysts Offer Insights on Healthcare Companies: Accuray (NASDAQ: ARAY), Evolus (NASDAQ: EOLS) and Caris Life Sciences, Inc. (NASDAQ: CAI)

Marc Goodman

Leerink Partners

―

Buy

―

Reiterated

10/07/25

Leerink Partners Keeps Their Buy Rating on Evolus (EOLS)

Balaji Prasad

Barclays

$22→$25

Buy

255.11%

Upside

Reiterated

03/05/25

Barclays Reaffirms Their Buy Rating on Evolus (EOLS)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Evolus

1 Month

xxx

Success Rate

10/21 ratings generated profit

Average Return

+7.25%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 47.62% of your transactions generating a profit, with an average return of +7.25% per trade.

3 Months

xxx

Success Rate

8/21 ratings generated profit

Average Return

+12.11%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 38.10% of your transactions generating a profit, with an average return of +12.11% per trade.

1 Year

Douglas TsaoH.C. Wainwright

Success Rate

10/22 ratings generated profit

Average Return

-7.31%

reiterated a buy rating 13 days ago

Copying Douglas Tsao's trades and holding each position for 1 Year would result in 45.45% of your transactions generating a profit, with an average return of -7.31% per trade.

2 Years

xxx

Success Rate

13/31 ratings generated profit

Average Return

-7.49%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 41.94% of your transactions generating a profit, with an average return of -7.49% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

EOLS Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, EOLS has received 9 Buy Ratings, 6 Hold Ratings, and 0 Sell Ratings. EOLS average Analyst price target in the past 3 months is 19.25.

Each month's total comprises the sum of three months' worth of ratings.

EOLS Financial Forecast

EOLS Earnings Forecast

Next quarter’s earnings estimate for EOLS is $0.05 with a range of $0.02 to $0.10. The previous quarter’s EPS was -$0.13. EOLS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year EOLS has Performed in-line its overall industry.

EOLS Sales Forecast

Next quarter’s sales forecast for EOLS is $91.33M with a range of $89.42M to $93.70M. The previous quarter’s sales results were $68.97M. EOLS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year EOLS has Performed in-line its overall industry.

EOLS Stock Forecast FAQ

What is EOLS’s average 12-month price target, according to analysts?

Based on analyst ratings, Evolus Inc’s 12-month average price target is 19.25.

What is EOLS’s upside potential, based on the analysts’ average price target?

Evolus Inc has 173.44% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is EOLS a Buy, Sell or Hold?

Evolus Inc has a consensus rating of Strong Buy which is based on 5 buy ratings, 1 hold ratings and 0 sell ratings.

What is Evolus Inc’s price target?

The average price target for Evolus Inc is 19.25. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $20.00 ,the lowest forecast is $18.00. The average price target represents 173.44% Increase from the current price of $7.04.

What do analysts say about Evolus Inc?

Evolus Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.

How can I buy shares of EOLS?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Evolus (EOLS) Stock Forecast & Price Target

EOLS Analyst Ratings

EOLS Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Evolus

EOLS Analyst Recommendation Trends

EOLS Financial Forecast

EOLS Earnings Forecast

EOLS Sales Forecast

EOLS Stock Forecast FAQ

Detailed List of Analyst Forecasts